Research programme: TRPV3 antagonists - Glenmark Pharmaceuticals

Drug Profile

Research programme: TRPV3 antagonists - Glenmark Pharmaceuticals

Latest Information Update: 25 Jun 2015

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class
  • Mechanism of Action TRPV3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 03 May 2010 TRPV3 antagonists licensed to sanofi-aventis in North America, European Union, Japan, Brazil, Russia and China
  • 12 May 2008 Preclinical trials in Pain in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top